Genmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading Volume - What's Next?

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) saw an uptick in trading volume on Tuesday . 446,790 shares were traded during mid-day trading, a decline of 32% from the previous session's volume of 656,442 shares.The stock last traded at $22.40 and had previously closed at $22.78.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on GMAB shares. Royal Bank of Canada raised Genmab A/S from a "sector perform" rating to an "outperform" rating in a research report on Monday, July 15th. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, September 9th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Wednesday, October 16th. JPMorgan Chase & Co. restated a "neutral" rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Finally, Redburn Atlantic assumed coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a "buy" rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Price Performance

The company has a market capitalization of $15.06 billion, a P/E ratio of 18.80, a P/E/G ratio of 0.67 and a beta of 0.99. The business has a 50-day moving average of $24.68 and a 200-day moving average of $26.50.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). The company had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. Sell-side analysts predict that Genmab A/S will post 1.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its stake in shares of Genmab A/S by 360.5% in the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company's stock worth $882,000 after purchasing an additional 23,094 shares during the last quarter. Capital International Investors raised its position in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company's stock worth $130,805,000 after buying an additional 315,355 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Genmab A/S by 26.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company's stock valued at $5,480,000 after acquiring an additional 45,376 shares during the period. Choreo LLC acquired a new stake in shares of Genmab A/S in the second quarter worth $776,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.